ArticleDigestive diseases and sciences2026
Effect of Concomitant Immunomodulator Use by UST-CDST Classification on Clinical Relapse in Crohn's Disease Patients Treated with Ustekinumab: A Multicenter Study.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimUstekinumab (UST) Clinical Decision Support Tool (UST-CDST) was introduced to predict clinical remission at 16 weeks in patients with active CD who were treated with UST enrolled in the UNITI trial. Controversy still remained regarding the effectiveness of UST with concomitant immunomodulator and the criteria for patients who could benefit from concomitant therapy. The aim of the study was to evaluate the effect of UST with concomitant immunomodulator on relapses in patients with CD and the feasibility of UST-CDST as a patient selection tool for concomitant immunomodulator.
methodsBetween January 2021 and July 2023, patients with moderate-to-severe CD refractory to conventional therapies and treated with UST were enrolled at four tertiary hospitals. Patients who achieved a clinical response after UST induction were included. Clinical relapse (CR) was defined as admission, steroid, surgery, or biologics changes. Kaplan-Meier analysis was performed to evaluate the efficacy of UST with immunomodulator and to investigate the screening ability of UST-CDST for concomitant immunomodulator selection.
resultsAmong 53 patients, cumulative relapse rate differed significantly between those receiving concomitant immunomodulator and those treated with UST alone (p = 0.024). Patients classified as low-to-intermediate-probability responders by UST-CDST who received combination therapy demonstrated a significantly higher relapse-free survival rate (p = 0.046). However, this trend was not observed in high-probability responders (p = 0.439).
conclusionIn this study, the concomitant use of an immunomodulator with UST was associated with a reduced risk of CR. This effect was particularly evident in the low-to-intermediate-probability responder group. The UST-CDST might serve as a useful tool for guiding decisions regarding the use of concomitant immunomodulator in clinical practice.
Indexed as
Identifiers
41721961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.